Top

Journal of Assisted Reproduction and Genetics

Published in:

01-05-2008 | Original Paper

Timing and duration of use of GnRH antagonist down-regulation for IVF/ICSI cycles have no impact on oocyte quality or pregnancy outcomes

Authors: Laura Detti, Dana R. Ambler, Frank D. Yelian, Michael L. Kruger, Michael P. Diamond, Elizabeth E. Puscheck

Published in: Journal of Assisted Reproduction and Genetics | Issue 5/2008

Abstract

Purpose

To evaluate whether oocyte quality, implantation and pregnancy outcomes in in vitro fertilization (IVF)/intra-cytoplasmic sperm injection (ICSI) are related to the duration of gonadotropin-releasing hormone (GnRH)-antagonist use or the timing of its initiation.

Methods

Retrospective cohort study of 178 conventional IVF/ICSI cycles. All patients underwent ovarian stimulation with gonadotropins and GnRH-antagonist for pituitary down-regulation. Spearman correlations and logistic regression were used for statistical analysis.

Results

There was no correlation between the duration of use or the timing of initiation of GnRH-antagonist with oocyte quality or implantation and pregnancy outcomes. Oocyte quality was influenced by the peak estradiol. Implantation was influenced by the patient’s age. Early pregnancy loss, by the endometrial thickness on human chorionic gonadotropin-day. Ongoing pregnancy was independent from the variables evaluated.

Conclusions

GnRH-antagonist duration of use or starting day did not influence oocyte quality, implantation rates, and pregnancy rates. We hypothesize that a follicle stimulating hormone/luteinizing hormone dose increase when antagonist was started, may have had an impact on our findings.

Fluker M, Grifo J, Leader A, Levy M, Meldrum D, Muasher SJ, Rinehart J, Rosenwaks Z, Scott RT, Schoolcraft W, Shapiro DB, North American Ganirelix Study Group. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril 2001;75:38–45.PubMedCrossRef

Borm G, Mannaerts B. Treatment with the gonadotropin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group. Hum Reprod 2000;15:1490–8.PubMedCrossRef

Lindheim SR, Morales AJ. GnRH antagonists followed by a decline in serum estradiol results in adverse outcomes in donor oocyte cycles. Hum Reprod 2003;18:2048–51.PubMedCrossRef

Al-Inany HG, Abou-Setta AM, Aboulghar M. Gonadotropin-releasing hormone antagonists for assisted conception. Cochrane Database Syst Rev 2006;3:CD001750.PubMed

Acevedo B, Sanchez M, Gomez JL, Cuadros J, Ricciarelli E, Hernandez ER. Luteinizing hormone supplementation increases pregnancy rates in gonadotropin-releasing hormone antagonist donor cycles. Fertil Steril 2004;82:343–7.PubMedCrossRef

Cedrin-Durnerin I, Grange-Dujardin D, Laffy A, Parneix I, Massin N, Galey J, Theron L, Wolf JP, Conord C, Clement P, Jayot S, Hugues JN. Recombinant human LH supplementation during GnRH antagonist administration in IVF/ICSI cycles: a prospective randomized study. Hum Reprod 2004;19:1979–84.PubMedCrossRef

Hernandez ER. Embryo implantation and GnRH-antagonists. Hum Reprod 2000;15:1211–6.PubMedCrossRef

Duijkers IJ, Klipping C, Willemsen WN, Krone D, Schneider E, Niebch G, Hermann R. Single and multiple dose pharmacokinetics and pharmacodynamics of the gonadotropin-releasing hormone antagonist cetrorelix in healthy female volunteers. Hum Reprod 1998;13:2392–8.PubMedCrossRef

Murdoch WJ. Immunolocalization of a gonadotropin-releasing hormone receptor site in murine endometrium that mediates apoptosis. Cell Tissue Res 1995;282:527–9.PubMedCrossRef

10.

Raga F, Casañ EM, Kruessel JS, Wen Y, Huang HY, Nezhat C, Polan ML. Quantitative gonadotropin-releasing hormone gene expression and immunohistochemical localization in human endometrium throughout the menstrual cycle. Biol Reprod 1998;59:661–9.PubMedCrossRef

11.

Grundker C, Schlotawa L, Viereck V, Eicke N, Horst A, Kairies B, Emons G. Antiproliferative effects of the GnRH antagonist cetrorelix and of GnRH-II on human endometrial and ovarian cancer cells are not mediated through the GnRH type I receptor. Eur J Endocrinol 2004;151:141–9.PubMedCrossRef

12.

Ruan HC, Zhu XH, Luo Q, Liu AX, Qian YL, Zhou CY, Jin F, Huang HF, Sheng JZ. Ovarian stimulation with GnRH agonist, but not GnRH antagonist, partially restores the expression of endometrial integrin beta3 and leukaemia-inhibitory factor and improves uterine receptivity in mice. Hum Reprod 2006;21:2521–9.PubMedCrossRef

13.

Xavier P, Gamboa C, Calejo L, Silva J, Stevenson D, Nunes A, Martinez-de-Oliveira J. A randomised study of GnRH antagonist (cetrorelix) versus agonist (busereline) for controlled ovarian stimulation: effect on safety and efficacy. Eur J Obstet Gynecol Reprod Biol 2005;120:185–9.PubMedCrossRef

14.

Kolibianakis E, Bourgain C, Albano C, Osmanagaoglu K, Smitz J, Van Steirteghem A, Devroey P. Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin releasing hormone antagonists, and human chorionic gonadotropin on endometrial maturation on the day of oocyte pick-up. Fertil Steril 2002;78:1025–9.PubMedCrossRef

15.

Papanikolaou EG, Camus M, Fatemi HM, Tournaye H, Verheyen G, Van Steirteghem A, Devroey P. Early pregnancy loss is significantly higher after day 3 single embryo transfer than after day 5 single blastocyst transfer in GnRH antagonist stimulated IVF cycles. Reprod Biomed Online 2006;12:60–5.PubMedCrossRef

Title: Timing and duration of use of GnRH antagonist down-regulation for IVF/ICSI cycles have no impact on oocyte quality or pregnancy outcomes
Authors: Laura Detti
Dana R. Ambler
Frank D. Yelian
Michael L. Kruger
Michael P. Diamond
Elizabeth E. Puscheck
Publication date: 01-05-2008
Publisher: Springer US
Published in: Journal of Assisted Reproduction and Genetics / Issue 5/2008
Print ISSN: 1058-0468
Electronic ISSN: 1573-7330
DOI: https://doi.org/10.1007/s10815-008-9217-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Timing and duration of use of GnRH antagonist down-regulation for IVF/ICSI cycles have no impact on oocyte quality or pregnancy outcomes

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2008

Comparison of the efficacy of the aromatase inhibitor letrozole and clomiphen citrate gonadotropins in controlled ovarian hyperstimulation: a prospective, simply randomized, clinical trial

Isolation of the human ePAB and ePABP2 cDNAs and analysis of the expression patterns

Follicular fluid VEGF levels directly correlate with perifollicular blood flow in normoresponder patients undergoing IVF

MicroRNA expression in preimplantation mouse embryos from Ped gene positive compared to Ped gene negative mice

Chromosome heteromorphisms: an impact on infertility

Evaluation of sperm selection procedure based on hyaluronic acid binding ability on ICSI outcome